| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Purity: ≥98%
Daunorubicin HCl (Daunomycin; RP-13057; Rubidomycin; Ondena; Rubilem; DNM; DNR; DRB; FI6339; RP13057), the hydrochloride salt of daunorubicin, is an anthracycline analog and a topoisomerase II inhibitor which is approved for use as an antibiotic and chemotherapeutic drug.
| Targets |
Daunorubicins/Doxorubicins; Topoisomerase II
|
|
|---|---|---|
| ln Vitro |
|
|
| ln Vivo |
|
|
| Enzyme Assay |
Inhibition of DNA and RNA synthesis by daunorubicin in sensitive and resistant Ehrlich ascites tumor cells in vitro [2].
|
|
| Cell Assay |
Cell Line: Molt-4 cells (a human T-lymphoblastic leukemia cell line), L3.6 cells (metastatic human pancreatic cell line)
Concentration: 7 nM-1.9 μM Incubation Time: 72 h Result: Inhibited cell viability with IC50 values of 40 nM (Molt-4) and 400 nM (L3.6). |
|
| Animal Protocol |
|
|
| References |
|
|
| Additional Infomation |
Daunorubicin Hydrochloride can cause developmental toxicity according to state or federal government labeling requirements.
Daunorubicin hydrochloride appears as orange-red powder. Thin red needles decomposing at 188-190 °C. An anti-cancer drug. Daunorubicin hydrochloride is an anthracycline. Daunorubicin Hydrochloride is the hydrochloride salt of an anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin. Daunorubicin exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis. A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS. |
| Molecular Formula |
C27H29NO10.HCL
|
|---|---|
| Molecular Weight |
563.98
|
| Exact Mass |
563.155
|
| Elemental Analysis |
C, 57.50; H, 5.36; Cl, 6.29; N, 2.48; O, 28.37
|
| CAS # |
23541-50-6
|
| Related CAS # |
1884557-85-0; 20830-81-3; 371770-68-2 (citrate); 23541-50-6 (HCl)
|
| PubChem CID |
62770
|
| Appearance |
Red solid powder
|
| Boiling Point |
770ºC at 760 mmHg
|
| Melting Point |
188 - 190ºC
|
| Flash Point |
419.5ºC
|
| Vapour Pressure |
6.99E-26mmHg at 25°C
|
| LogP |
2.531
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
39
|
| Complexity |
960
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
Cl[H].O([C@@]1([H])C([H])([H])[C@@]([H])([C@@]([H])([C@]([H])(C([H])([H])[H])O1)O[H])N([H])[H])[C@]1([H])C2C(=C3C(C4C(=C([H])C([H])=C([H])C=4C(C3=C(C=2C([H])([H])[C@@](C(C([H])([H])[H])=O)(C1([H])[H])O[H])O[H])=O)OC([H])([H])[H])=O)O[H]
|
| InChi Key |
GUGHGUXZJWAIAS-QQYBVWGSSA-N
|
| InChi Code |
InChI=1S/C27H29NO10.ClH/c1-10-22(30)14(28)7-17(37-10)38-16-9-27(35,11(2)29)8-13-19(16)26(34)21-20(24(13)32)23(31)12-5-4-6-15(36-3)18(12)25(21)33;/h4-6,10,14,16-17,22,30,32,34-35H,7-9,28H2,1-3H3;1H/t10-,14-,16-,17-,22+,27-;/m0./s1
|
| Chemical Name |
(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride
|
| Synonyms |
Daunomycin HCl; RP 13057; Rubidomycin; RP-13057; RP13057; Daunomycin hydrochloride; daunomycin HCl; daunorubidomycine; US trade names: Cerubidine; Rubidomycin; Foreign brand names: Cerubidin; Daunoblastin; Daunoblastina; Ondena; Rubilem; Abbreviations: DNM; DNR; DRB; Code names: FI6339; RP13057
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.69 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.69 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: Saline: 30 mg/mL Solubility in Formulation 4: 33.33 mg/mL (59.10 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7731 mL | 8.8656 mL | 17.7311 mL | |
| 5 mM | 0.3546 mL | 1.7731 mL | 3.5462 mL | |
| 10 mM | 0.1773 mL | 0.8866 mL | 1.7731 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT02085408 | Active Recruiting |
Drug: Daunorubicin Drug: Cytarabine |
Adult Acute Monocytic Leukemia (M5b) Adult Erythroleukemia (M6a) |
ECOG-ACRIN Cancer Research Group | February 4, 2011 | Phase 3 |
| NCT02013648 | Active Recruiting |
Drug: Daunorubicin Drug: Idarubicin |
Acute Myeloid Leukemia (AML) |
University of Ulm | July 2014 | Phase 3 |
| NCT03836209 | Active Recruiting |
Drug: Daunorubicin Drug: Cytarabine |
Acute Myeloid Leukemia | PrECOG, LLC. | December 6, 2019 | Phase 2 |
| NCT03709758 | Recruiting | Drug: Venetoclax Drug: Daunorubicin |
Acute Myeloid Leukemia | Dana-Farber Cancer Institute | October 17, 2018 | Phase 1 |
| NCT05832320 | Recruiting | Drug: Daunorubicin Drug: Etoposide |
Induction Therapy Oral |
Peking University People's Hospital |
January 1, 2023 | Not Applicable |
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
